Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Mov Disord. 2020 Jul;35(7):1233-1238. doi: 10.1002/mds.28026. Epub 2020 Apr 27.
With disease-modifying treatment strategies on the horizon, stratification of individual patients at the earliest stages of Parkinson's disease (PD) is key-ideally already at clinical disease onset. Blood levels of neurofilament light chain (NfL) provide an easily accessible fluid biomarker that might allow capturing the conversion from prodromal to manifest PD.
We assessed longitudinal serum NfL levels in subjects converting from prodromal to manifest sporadic PD (converters), at-risk subjects, and matched controls (72 participants with ≈4 visits), using single-molecule array (Simoa) technique.
While NfL levels were not increased at the prodromal stage, subjects converting to the manifest motor stage showed a significant intraindividual acceleration of the age-dependent increase of NfL levels.
The temporal dynamics of intraindividual NfL blood levels might mark the conversion to clinically manifest PD, providing a potential stratification biomarker for individual disease onset in the advent of precision medicine for PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
随着针对疾病修饰治疗策略的出现，在帕金森病（PD）的最早阶段对个体患者进行分层是关键——理想情况下，应在临床疾病发病时进行。神经丝轻链（NfL）的血液水平提供了一种易于获取的液体生物标志物，可能能够捕捉从前驱期到显性 PD 的转化。
我们使用单分子阵列（Simoa）技术评估了从前驱期到显性散发性 PD（转化者）、高危受试者和匹配对照者（72 名参与者，约 4 次就诊）中纵向血清 NfL 水平。
虽然在前驱期 NfL 水平没有增加，但转化为显性运动期的受试者表现出 NfL 水平随年龄增长的个体内加速增加。
个体内 NfL 血液水平的时间动态可能标志着向临床显性 PD 的转化，为 PD 精准医学时代的个体疾病发病提供了潜在的分层生物标志物。© 2020 作者。运动障碍由 Wiley 期刊代表国际帕金森和运动障碍协会出版。
